Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studies
and support ongoing partnership discussions

Topline results expected in early Q4 2024

Read more at globenewswire.com